Loopbaan van Thomas Harding
Eerdere bekende functies van Thomas Harding
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01-10-2019 | 10-07-2023 |
Opleiding van Thomas Harding
University of Bristol | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 2 |
Verenigde Staten | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Undergraduate Degree | 1 |
Sectoraal
Consumer Services | 2 |
Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Beurs
- Insiders
- Thomas Harding
- Ervaring